Other
Tics
1
Pipeline Programs↗
150
Active Trials↗
388
Companies Involved↗
Tics is an early-stage landscape with 1 program across 388 companies. The most active players are Boehringer Ingelheim, AstraZeneca, Pfizer. 1 therapy is approved.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved1
Analysis
Trial Status
2,350
clinical trials
Completed1,950 · 83%
Unknown status121 · 5%
Terminated91 · 4%
Recruiting84 · 4%
Not yet recruiting38 · 2%
Withdrawn36 · 2%
Other30 · 1%
Clinical Trials
Trial Activity
2350 trials
Page 1 of 157
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)